GUBRA Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology. It also has a portfolio strategy of potential drug candidates in the form of upfront payments, research payments, milestone payments, and royalties; and investments targeting as sets promoting the green transition. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Camurus' FluidCrystal technology to develop a therapy for hypoparathyroidism; Amylyx Pharmaceuticals to develop a GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is headquartered in Horsholm, Denmark.…
Industry Peers
BiotechnologyKey Statistics
About Gubra (CPH: GUBRA)
›
Gubra (CPH: GUBRA) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 330 employees.
The shares were at 261.00 DKK on 20 November 2026, down 30.9% over 52 weeks. Its 52-week range is 264.00 DKK to 557.50 DKK, and it trades at the bottom of that range.
Its market capitalisation is 4.38B DKK.
Gubra reports return on equity of 147.5%, an operating margin of -73.1% and revenue down 94.9% year over year.
It holds more cash than debt, a net cash position of 714.64M DKK. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 515.00 DKK is 97.3% above the current price. The next earnings report is expected on 3 March 2027.